How much funding has Bionyra Pharma raised?

Bionyra Pharma has raised $165.0M in total funding, most recently a series a round.

When was Bionyra Pharma founded?

Bionyra Pharma was founded in 2025.

Where is Bionyra Pharma headquartered?

Bionyra Pharma is headquartered in Paris, France.

What industry is Bionyra Pharma in?

Bionyra Pharma operates in Biotech.

How many employees does Bionyra Pharma have?

Bionyra Pharma has 1-10 employees.

Bionyra Pharma

Q: Who are Bionyra Pharma's investors?

Bionyra Pharma's investors include Jeito Capital, Sofinnova Partners, Arkin Bio Ventures, Sanofi Ventures, Sixty Degree Capital, Apollo Health Ventures.

Next-generation biologics for severe immunological and inflammatory diseases

Paris, France · Founded 2025 · $165.0M raised

Biotech

Headquarters: Paris
Employees: 1–10
Founded: 2025
Business Model: B2B

Website: bionyrapharma.com
Total Funding: $165.0M
Last Round: $165.0M Series AJun 2026
Rounds: 1

About

Bionyra Pharma is a Paris-based clinical-stage biopharmaceutical company developing mono and multispecific antibodies with half-life extension technology for immune-mediated inflammatory diseases. The company's pipeline targets atopic dermatitis and inflammatory bowel disease, leveraging next-generation biologic modalities designed to improve upon current standard-of-care antibody therapies. Founded in August 2025 by former Sanofi R&D executive Dr. Frédéric Marrache and Sofinnova Partners, Bionyra launched with a $165 million oversubscribed Series A co-led by Jeito Capital and Sofinnova Partners — the largest biotech Series A in French history.

Summary

Bionyra Pharma is a Biotech company based in Paris, France, founded in 2025. It has raised $165.0M in total across 1 round, most recently a $165.0M Series A round in Jun 2026. Investors include Jeito Capital, Sofinnova Partners and Arkin Bio Ventures.